Chlitina Holding Limited (麗豐-KY, TWSE: 4137) today (August 21) announced its second quarter 2025 financial results. Consolidated revenue for Q2 reached NT$950 million, up 19% quarter-over-quarter; operating income was NT$147 million, up 54% QoQ; net income attributable to the parent company was NT$216 million, up 287% QoQ. Earnings per share (EPS) for the quarter were NT$2.62. In renminbi terms, net income attributable to the parent was RMB 49.72 million, up 302% QoQ and 2% YoY. For the first half of 2025, consolidated revenue totaled NT$1.75 billion, operating income NT$243 million, net income attributable to the parent company NT$272 million, and EPS NT$3.3.

Following amendments to the company’s Articles of Incorporation, a “more-than-once-per-year” dividend policy is expected, allowing the company to share operational results with all shareholders.

Chlitina Holding Limited (hereinafter “Chlitina-KY,” Stock Code: 4137) announced the Global Launch Conference of the Chlitina Golden Remedy in Wuhan, China, on May 9. At the event, Chlitina unveiled its major innovation of the year, the “Skin Radiance Refining Essence Series,” achieving on-site sales of over RMB 10 million in a single day, and underscoring Chlitina’s leading position in the premium skincare market.

Chlitina Holding Limited (麗豐-KY) recently announced its November revenue. While this year’s performance has been affected by external economic headwinds, the Group continues to uphold its commitment to brand development, strengthening its capabilities amid challenges and preparing for future recovery.